Abstract:Alzheimer's disease (AD) shows a high pathological and symptomatological heterogeneity. To study this heterogeneity, we have developed a patient stratification technique based on one of the most significant risk factors for the development of AD: genetics. We addressed this challenge by including network biology concepts, mapping genetic variants data into a brain-specific protein–protein interaction (PPI) network, and obtaining individualized PPI scores that we then used as input for a clustering technique. We then phenotyped each obtained cluster regarding genetics, sociodemographics, biomarkers, fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging, and neurocognitive assessments. We found three clusters defined mainly by genetic variants found in MAPT , APP , and APOE , considering known variants associated with AD and other neurodegenerative disease genetic architectures. Profiling of these clusters revealed minimal variation in AD symptoms and pathology, suggesting different biological mechanisms may activate the neurodegeneration and pathobiological patterns behind AD and result in similar clinical and pathological presentations, even a shared disease diagnosis. Lastly, our research highlighted MAPT , APP , and APOE as key genes where these genetic distinctions manifest, suggesting them as potential targets for personalized drug development strategies to address each AD subgroup individually.

What problem does this paper attempt to address?

### Problems the paper attempts to solve The paper aims to solve the high heterogeneity problem of Alzheimer’s disease (AD) through patient stratification techniques based on genetics. Specifically, the authors developed a new method, using the concept of network biology, to map genetic variation data into the brain - specific protein - protein interaction (PPI) network, thereby obtaining individualized PPI scores. These scores are then used as input for the clustering algorithm to identify different patient subgroups. ### Main research objectives 1. **Discover new genetic patterns**: By analyzing the impact of genetic variation on the PPI network, discover genetic patterns that may lead to different pathophysiological or symptomatic characteristics. 2. **Understand the biological mechanisms of different subgroups**: Through detailed genotyping, sociodemographic, biomarker, FDG - PET imaging, and neurocognitive assessments of each subgroup, reveal the biological differences between different subgroups. 3. **Potential therapeutic targets**: Identify key genes (such as MAPT, APP, and APOE), whose genetic variations in different subgroups may become potential targets for personalized drug development. ### Research background Despite decades of research, there are still many unknown factors in Alzheimer’s disease. Its degenerative, complex, and heterogeneous nature makes the development of early diagnosis and disease - modifying treatments very challenging. Patient stratification techniques, by identifying patient subgroups based on sociodemographic, clinical, or molecular data, are helpful for the design of clinical trials and clinical practice, providing timely diagnosis and the most appropriate treatment options. ### Method overview 1. **Data selection**: Use the genetic cohort of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to select genetic variations related to AD and other neurodegenerative diseases. 2. **PPI network construction**: Connect the genes where these genetic variations are located to a brain - specific PPI sub - network. 3. **Individualized PPI scoring**: Map each subject’s genetic variation to the edges of the PPI network to generate individualized edge scores. 4. **Clustering analysis**: Use these scores as input, apply a similarity - based clustering model to identify different genetic subgroups. 5. **Subgroup characterization**: Describe the characteristics of each subgroup from multiple perspectives such as genotyping, sociodemographic, biomarker, FDG - PET imaging, and neurocognitive assessment. ### Main findings 1. **Three main subgroups**: Through clustering analysis, three main genetic subgroups were discovered, defined as Cluster 1, Cluster 2, and Cluster 3 respectively. 2. **Key genes**: These subgroups are mainly defined by the genetic variations of the MAPT, APP, and APOE genes. - **Cluster 1**: Mainly affected by MAPT gene variation, showing higher CSF tTau and pTau values, as well as a higher proportion of the APOE E4/E4 risk genotype. - **Cluster 2**: Mainly defined by differences from the other two subgroups, less affected by MAPT and APP gene variations. - **Cluster 3**: Mainly affected by APP gene variation, containing some rare APP variations that are related to the risk of sporadic AD. 3. **Neuroimaging and cognitive features**: Different subgroups show different characteristics in FDG - PET imaging and neurocognitive assessment, especially in the metabolic changes in the temporal and parietal lobes. ### Conclusion This study successfully identified different subgroups of Alzheimer’s disease through patient stratification techniques based on genetics, and revealed significant differences in genetics, biomarkers, and neuroimaging among these subgroups. These findings not only help to understand the heterogeneity of AD, but also provide an important basis for the development of personalized treatment strategies.

Genetic-based patient stratification in Alzheimer's disease

Towards cascading genetic risk in Alzheimer’s disease

Advances in Genetic and Molecular Understanding of Alzheimer's Disease

Pathology Steered Stratification Network for Subtype Identification in Alzheimer's Disease

Towards cascading genetic risk in Alzheimer's disease

Exploring the Genetic Heterogeneity of Alzheimer's Disease: Evidence for Genetic Subtypes

Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles

Polygenic Hazard Score Associated Multimodal Brain Networks along the Alzheimer's Disease Continuum.

Characterizing the clinical heterogeneity of early symptomatic Alzheimer's disease: a data-driven machine learning approach

Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms

Brain Cell-based Genetic Subtyping and Drug Repositioning for Alzheimer Disease

Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals

Identification of novel risk genes for Alzheimer's disease by integrating genetics from hippocampus

Clustering of Alzheimer’s and Parkinson’s disease based on genetic burden of shared molecular mechanisms

System-Level Analysis of Alzheimer's Disease Prioritizes Candidate Genes for Neurodegeneration

Genetic, Clinical Underpinnings of Brain Change along Two Neuroanatomical Dimensions of Clinically-defined Alzheimer’s Disease

Discovering Alzheimer’s Disease Subtypes with Imaging and Genetic Signatures Via Multi‐view Weakly‐supervised Deep Clustering

Systems genetic dissection of Alzheimer's disease brain gene expression networks

Integrating amyloid imaging and genetics for early risk stratification of Alzheimer's disease

Network dynamics-based subtyping of Alzheimer's disease with microglial genetic risk factors

Identifying and evaluating clinical subtypes of Alzheimer’s disease in care electronic health records using unsupervised machine learning